secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-062054
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports Q2 FY2024 net loss of $114.3M; positive CHMP opinion for ONS-5010 in EU
--------------------------------------------------------------------------------

- Net loss of $114.3M ($8.01/sh); adjusted net loss of $22.1M ($1.55/sh) vs $6.7M loss year ago.
- CHMP issued positive opinion for ONS-5010/LYTENAVA in EU; EC decision expected within ~67 days.
- NORSE EIGHT trial >30% enrolled; topline readout planned in Q4 CY2024; BLA resubmission by end of CY2024.
- UK MAA submitted under International Recognition Procedure.
- Company believes sufficient capital to fund potential FDA approval and commercial launch assuming warrant exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924062054/0001104659-24-062054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924062054/tm2414392d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-062054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer